Maria Queralt Salas

Dr. Maria Queralt Salas

Institut Català d'Oncologia
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
APAlexandra Pedraza
Alexandra Pedraza
MSMaria Queralt Salas
Maria Queralt Salas
LRLuis Gerardo Rodríguez-Lobato
Luis Gerardo Rodríguez-Lobato
SSSilvia Escribano Serrat
Silvia Escribano Serrat
MSMaría Suárez-Lledo
María Suárez-Lledo
CMCarmen Martínez
Carmen Martínez
Plasma biomarkers of endothelial dysfunction have been postulated for the diagnosis and prognosis of acute graft-versus-host disease (aGVHD). However, their use is not validated in clinical practice yet. The endothelial activation and stress index (EASIX), a simple score based on routine laboratory parameters, is considered to be an indirect marker of endothelial damage. High value of EASIX was correlated with worse non-relapse mortality (NRM) and overall survival (OS) and a high risk of sinusoidal obstructive syndrome (SOS) and transplant-associated thrombotic microangiopathy (TA-TMA). This study investigates the predictive value of plasma biomarkers and the EASIX score for the prediction of aGVHD. We assessed VCAM-1, TNFR1, and VWF:Ag plasma levels, and EASIX score before allogeneic hematopoietic stem cell transplantation (allo-HSCT), and on days 0, +3, +7, +14, and +21 in an experimental cohort (n=33). EASIX was transformed to a base-2 logarithm to perform the analysis. For the most relevant biomarkers, we estimate the optimal cut-off values and the discriminatory ability to differentiate patients with high-risk of aGVHD. The conclusions obtained in the experimental cohort were validated in a large cohort of 321 patients at the same institution. Plasma biomarkers and EASIX showed similar post-transplant dynamics consisting of a progressive increase. Multivariate analysis showed an association between high TNFR1 levels and Log-2 EASIX score on day +7 post-transplant with an increased likelihood of developing aGVHD (HR 1, P=0.002; HR 2.31, P=0.013, respectively). Patients with TNFR1 ≥1300 ng/mL (HR 7.19, P=0.006) and Log2-EASIX ≥3 (HR 14.7, P<0.001) at day +7 post-transplant were more likely to develop aGVHD with high predictive accuracy (C-index of 74% and 81%, respectively). In the validation cohort, patients with Log2-EASIX ≥ 3 on day +7 post-transplant presented a significantly higher incidence of grade II-IV aGVHD (HR 1.94, P=0.004) independent of GVHD prophylaxis (HR 0.38, P=0.004), conditioning regimen (HR 0.59, P=0.02) and type of donor (HR 2.38, P=0.014). Differential degree of endothelial damage can be measured using both EASIX score and plasma biomarkers in the early post-transplant period. Patients at risk of developing aGVHD could be easily identified by a high EASIX score. Both indicators of endothelial activation represent a promising approach to predict aGVHD.

5 February 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MSMaria Queralt Salas
Maria Queralt Salas
SPShruti Prem
Shruti Prem
EAEshetu G. Atenafu
Eshetu G. Atenafu
ALArjun Datt Law
Arjun Datt Law
WLWilson Lam
Wilson Lam
AVAuro Viswabandya
Auro Viswabandya

8 September 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
MPMarta Peña
Marta Peña
MSMaria Queralt Salas
Maria Queralt Salas
AMAlberto Mussetti
Alberto Mussetti
GMGabriel Moreno-González
Gabriel Moreno-González
ABAnna Bosch
Anna Bosch
ASAnna Sureda
Anna Sureda
The Endothelial Activation and Stress Index (EASIX) is a laboratory-based prognosis index defined as creatinine × lactate dehydrogenase/platelets. When measured at pretransplantation evaluation (EASIX-PRE), it predicts allogeneic hematopoietic cell transplantation (alloHCT) mortality. This study explores its ability to predict intensive care unit (ICU) admission and validates EASIX-PRE predictive power for overall survival (OS) and nonrelapse mortality (NRM) in 167 consecutive patients undergoing alloHCT. EASIX-PRE was calculated retrospectively in all patients and transformed into log2 values (log2-EASIX-PRE). Log2-EASIX-PRE predicted ICU admission (hazard ratio [HR], 1.41; P < .001), OS (HR, 1.19; P = .011), and NRM (HR, 1.28; P = .004). The most discriminating EASIX-PRE cutoff value for risk of ICU admission was the 75th percentile (2.795); for OS and NRM, it was the median value (1.703). Patients with EASIX-PRE >2.795 had higher incidence of ICU admission in comparison with patients with lower EASIX-PRE values (day +180, 35.8% vs 12.8%; HR, 2.28; P = .010). Additionally, patients with EASIX-PRE >1.073 had lower OS (2 years, 57.7% vs 68.7%; HR, 1.98; P = .006) and higher NRM (2 years, 38.7% vs 18.5%; HR, 2.92; P = .001) than patients with lower EASIX-PRE results. Log2-EASIX-PRE was not associated with incidence of transplantation-associated microangiopathy, sinusoidal obstruction syndrome, or acute graft-versus-host disease. This study proposes EASIX-PRE as a prognostic tool to identify patients undergoing alloHCT at increased risk of severe organ dysfunction and who would therefore require ICU admission. Early identification of patients at high risk of severe events could contribute to personalized intervention design. Additionally, it validates the association between EASIX-PRE and OS and NRM in those undergoing alloHCT.

11 May 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
APAmanda Isabel Pérez-Valencia
Amanda Isabel Pérez-Valencia
ECEnric Cascos
Enric Cascos
SCSara Carbonell-Ordeig
Sara Carbonell-Ordeig
PCPaola Andrea Charry
Paola Andrea Charry
MGMarta Gómez-Hernando
Marta Gómez-Hernando
MSMaria Queralt Salas
Maria Queralt Salas
This study investigates early cardiac events (ECEs) occurring during the first 180 days after allogeneic hematopoietic cell transplant (allo-HCT) in 416 adults receiving posttransplant cyclophosphamide (PTCY) (n = 258) or not receiving PTCY (n = 158). Total body irradiation (TBI) was given to 133 (31.9%) patients, of whom 111 (83.4%) received TBI combined with PTCY. The day +180 cumulative incidence function (CIF) of ECEs was 8.4%, with heart failure (n = 13) and pericardial complications (n = 11) being the most prevalent complications. The incidence of ECEs was higher in patients receiving PTCY, and receiving TBI. ECEs were more prevalent in haploidentical HCTs than in matched sibling donor, 10/10 HLA-matched unrelated donor, and 9/10 HLA-mismatched unrelated donor allo-HCTs. As for the ECE risk from the combination of PTCY and TBI, the multivariate analysis reported that patients receiving PTCY without TBI, TBI without PTCY, and TBI with PTCY were at higher risk for ECEs compared with patients receiving neither PTCY nor TBI. Pre-existing cardiac morbidity predicted ECEs. However, using high-dose CY-containing preparative regimens did not increase the risk for cardiac toxicity at +180 days after allo-HCT. ECEs were associated with higher nonrelapse mortality and lower overall survival. Considering that PTCY and TBI were predictors for ECEs, and the impact of this complication on transplant mortality, the implementation of cardiac monitoring plans could be appropriate in patients receiving these medications.

30 June 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MSMaria Queralt Salas
Maria Queralt Salas
EAEshetu G. Atenafu
Eshetu G. Atenafu
OBOra Bascom
Ora Bascom
LWLeeann Wilson
Leeann Wilson
WLWilson Lam
Wilson Lam
RKRajat Kumar
Rajat Kumar

6 November 2019 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MSMaria Queralt Salas
Maria Queralt Salas
AAAli Alahmari
Ali Alahmari
JLJeffrey Howard Lipton
Jeffrey Howard Lipton